Senseonics (NYSE:SENS) Reaches New 1-Year High – Still a Buy?

Senseonics Holdings, Inc. (NYSE:SENS) reached a new 52-week high on Wednesday . The stock traded as high as $0.95 and last traded at $0.99, with a volume of 3044314 shares traded. The stock had previously closed at $0.91.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. StockNews.com initiated coverage on Senseonics in a research note on Thursday, December 26th. They set a “sell” rating on the stock. HC Wainwright reissued a “buy” rating and set a $2.00 price objective on shares of Senseonics in a research report on Friday, November 15th.

Senseonics Stock Up 3.1 %

The stock’s 50 day moving average is $0.47 and its 200-day moving average is $0.41. The company has a quick ratio of 2.38, a current ratio of 2.47 and a debt-to-equity ratio of 59.17.

Senseonics (NYSE:SENS) last released its earnings results on Thursday, November 7th. The company reported ($0.04) EPS for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.01). The firm had revenue of $4.26 million during the quarter, compared to analysts’ expectations of $4.02 million. Senseonics had a negative net margin of 362.30% and a negative return on equity of 842.25%. On average, equities analysts anticipate that Senseonics Holdings, Inc. will post -0.14 earnings per share for the current fiscal year.

Insider Activity

In other Senseonics news, CEO Timothy T. Goodnow bought 315,000 shares of the stock in a transaction dated Tuesday, December 10th. The stock was purchased at an average cost of $0.31 per share, for a total transaction of $97,650.00. Following the completion of the acquisition, the chief executive officer now owns 11,310,355 shares of the company’s stock, valued at approximately $3,506,210.05. This trade represents a 2.86 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Frederick T. Sullivan purchased 124,933 shares of the business’s stock in a transaction that occurred on Thursday, December 12th. The stock was bought at an average price of $0.38 per share, for a total transaction of $47,474.54. Following the purchase, the chief financial officer now directly owns 2,478,844 shares in the company, valued at $941,960.72. The trade was a 5.31 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 3.60% of the company’s stock.

Hedge Funds Weigh In On Senseonics

Large investors have recently modified their holdings of the stock. Symmetry Partners LLC purchased a new position in Senseonics in the 3rd quarter worth about $164,000. GSA Capital Partners LLP bought a new stake in shares of Senseonics in the third quarter worth approximately $117,000. Geode Capital Management LLC grew its stake in shares of Senseonics by 3.2% in the third quarter. Geode Capital Management LLC now owns 5,838,396 shares of the company’s stock worth $2,042,000 after acquiring an additional 179,103 shares during the period. FMR LLC raised its holdings in shares of Senseonics by 48,267.2% during the third quarter. FMR LLC now owns 168,318 shares of the company’s stock valued at $59,000 after purchasing an additional 167,970 shares during the last quarter. Finally, Ridgecrest Wealth Partners LLC bought a new position in Senseonics during the fourth quarter valued at approximately $60,000. Hedge funds and other institutional investors own 12.36% of the company’s stock.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.